Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.
Pascual J, Gil-Gil M, Proszek P, Zielinski C, Reay A, Ruiz-Borrego M, Cutts R, Ciruelos Gil EM, Feber A, Muñoz-Mateu M, Swift C, Bermejo B, Herranz J, Margeli Vila M, Antón A, Kahan Z, Csöszi T, Liu Y, Fernandez-Garcia D, Garcia-Murillas I, Hubank M, Turner NC, Martín M. Pascual J, et al. Among authors: garcia murillas i. Clin Cancer Res. 2023 Oct 13;29(20):4166-4177. doi: 10.1158/1078-0432.CCR-23-0956. Clin Cancer Res. 2023. PMID: 37490393 Free PMC article.
Noninvasive detection of HER2 amplification with plasma DNA digital PCR.
Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, Smith IE, Ashworth A, Turner NC. Gevensleben H, et al. Clin Cancer Res. 2013 Jun 15;19(12):3276-84. doi: 10.1158/1078-0432.CCR-12-3768. Epub 2013 May 1. Clin Cancer Res. 2013. PMID: 23637122 Free PMC article.
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.
Pearson A, Proszek P, Pascual J, Fribbens C, Shamsher MK, Kingston B, O'Leary B, Herrera-Abreu MT, Cutts RJ, Garcia-Murillas I, Bye H, Walker BA, Gonzalez De Castro D, Yuan L, Jamal S, Hubank M, Lopez-Knowles E, Schuster EF, Dowsett M, Osin P, Nerurkar A, Parton M, Okines AFC, Johnston SRD, Ring A, Turner NC. Pearson A, et al. Clin Cancer Res. 2020 Feb 1;26(3):608-622. doi: 10.1158/1078-0432.CCR-18-4044. Epub 2019 Oct 7. Clin Cancer Res. 2020. PMID: 31591187
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials.
Turner NC, Swift C, Kilburn L, Fribbens C, Beaney M, Garcia-Murillas I, Budzar AU, Robertson JFR, Gradishar W, Piccart M, Schiavon G, Bliss JM, Dowsett M, Johnston SRD, Chia SK. Turner NC, et al. Clin Cancer Res. 2020 Oct 1;26(19):5172-5177. doi: 10.1158/1078-0432.CCR-20-0224. Epub 2020 Jun 16. Clin Cancer Res. 2020. PMID: 32546646 Clinical Trial.
Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis.
Fitzpatrick A, Iravani M, Mills A, Childs L, Alaguthurai T, Clifford A, Garcia-Murillas I, Van Laere S, Dirix L, Harries M, Okines A, Turner NC, Haider S, Tutt ANJ, Isacke CM. Fitzpatrick A, et al. Among authors: garcia murillas i. Clin Cancer Res. 2022 Mar 15;28(6):1180-1191. doi: 10.1158/1078-0432.CCR-21-3017. Clin Cancer Res. 2022. PMID: 34921020 Free PMC article.
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, Bellet M, Cortés J, Elliott R, Pancholi S, Baselga J, Dowsett M, Martin LA, Turner NC, Serra V. Herrera-Abreu MT, et al. Cancer Res. 2016 Apr 15;76(8):2301-13. doi: 10.1158/0008-5472.CAN-15-0728. Epub 2016 Mar 28. Cancer Res. 2016. PMID: 27020857 Free PMC article.
Assessing HER2 Amplification in Plasma cfDNA.
Garcia-Murillas I, Turner NC. Garcia-Murillas I, et al. Methods Mol Biol. 2018;1768:161-172. doi: 10.1007/978-1-4939-7778-9_10. Methods Mol Biol. 2018. PMID: 29717443
49 results